» Articles » PMID: 4926242

Clinical Studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037)

Overview
Journal Cancer Res
Specialty Oncology
Date 1971 Mar 1
PMID 4926242
Citations 14
Authors
Affiliations
Soon will be listed here.
Citing Articles

Principles of dose finding studies in cancer: a comparison of trial designs.

Jaki T, Clive S, Weir C Cancer Chemother Pharmacol. 2013; 71(5):1107-14.

PMID: 23299793 PMC: 3636432. DOI: 10.1007/s00280-012-2059-8.


Increased degradation rate of nitrososureas in media containing carbonate.

Seidegard J, Gronquist L, Tuvesson H, Gunnarsson P In Vitro Cell Dev Biol Anim. 2008; 45(1-2):32-4.

PMID: 18855076 DOI: 10.1007/s11626-008-9147-4.


A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Gietema J, De Vries E, Sleijfer D, Willemse P, Guchelaar H, Uges D Br J Cancer. 1993; 67(2):396-401.

PMID: 8431374 PMC: 1968188. DOI: 10.1038/bjc.1993.73.


Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.

KARI P, McConnell W, Finkel J, Hill D Cancer Chemother Pharmacol. 1980; 4(4):243-8.

PMID: 7438326 DOI: 10.1007/BF00255268.


Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice.

Fisher R, Mandell G, Bostick F, McMenamin M, Anderson T Clin Exp Immunol. 1980; 39(2):416-25.

PMID: 6446427 PMC: 1538078.